Advertisement

Topics

ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

2014-08-27 03:18:02 | BioPortfolio

Summary

RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with topotecan hydrochloride may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of giving ABT-888 together with topotecan hydrochloride and to see how well it works in treating patients with advanced solid tumors or relapsed or refractory ovarian epithelial cancer or primary peritoneal cancer.

Description

OBJECTIVES:

- To determine the maximum tolerated dose of ABT-888 and topotecan hydrochloride in patients with advanced solid tumors. (Phase I)

- To identify any pharmacokinetic interactions between ABT-888 and topotecan hydrochloride. (Phase I)

- To determine whether topotecan hydrochloride stimulates ADP-ribose polymer formation in circulating peripheral blood mononuclear cells. (Phase I)

- To determine whether ABT-888 inhibits basal or topotecan hydrochloride-stimulated ADP-ribose polymer formation. (Phase I)

- To identify any antitumor activity of this regimen, as assessed by objective response, in patients with advanced solid tumors. (Phase I)

- To assess the progression-free survival of patients with relapsed or refractory ovarian epithelial cancer or primary peritoneal cancer treated with this regimen. (Phase II)

- To assess the toxicity of this regimen in patients with ovarian epithelial cancer or primary peritoneal cancer. (Phase II)

- To determine whether topotecan hydrochloride stimulates ADP-ribose polymer formation in circulating tumor cells and whether ABT-888 modulates this. (Phase II)

- To assess differences in the toxicity and/or efficacy of this regimen based on BRCA1/2 mutational status. (Phase II)

- To determine whether pretreatment tumor cell levels of topoisomerase I, poly (ADP-ribose) polymerase, BRCA1, BRCA2, XRCC1, TDP1, P-glycoprotein, or BCRP predict response to this regimen. (Phase II)

- To identify, in an exploratory manner, any transcriptional profiles that may predict response to this regimen. (Phase II)

OUTLINE: Patients receive oral ABT-888 once daily on days 1-3, 8-10, and 15-17*. Patients also receive topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients do not receive ABT-888 on days 1-3 during course 2.

Patients undergo blood and urine sample collection periodically for pharmacokinetic, pharmacogenetic, and other correlative laboratory studies. Patients enrolled in phase II also undergo tumor tissue collection at baseline for biomarker laboratory studies.

After completion of study treatment, patients are followed up every 3-6 months for up to 5 years.

PROJECTED ACCRUAL: A total of 104 patients (56 for phase I and 48 for phase II) will be accrued for this study.

Study Design

Primary Purpose: Treatment

Conditions

Ovarian Cancer

Intervention

topotecan hydrochloride, veliparib, laboratory biomarker analysis, pharmacological study

Status

Not yet recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:02-0400

Clinical Trials [2725 Associated Clinical Trials listed on BioPortfolio]

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

This randomized phase II trial studies how well topotecan hydrochloride and carboplatin with or without veliparib work in treating patients with myeloproliferative disorders that have spre...

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

This phase II clinical trial is studying the how well veliparib, topotecan hydrochloride, and filgrastim or pegfilgrastim work in treating patients with persistent or recurrent cervical ca...

Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

This phase I trial studies the side effects and best dose of veliparib when given together with irinotecan hydrochloride in treating patients with cancer that has spread to other parts of ...

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

This phase I trial studies the side effects and best dose of tivantinib and topotecan hydrochloride in treating patients with advanced or metastatic solid tumors. Tivantinib and topotecan ...

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

This phase I trial studies the side effects and the best dose of veliparib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with ovarian cancer, ...

PubMed Articles [33711 Associated PubMed Articles listed on BioPortfolio]

Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.

Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhi...

Synovasure 'quick test' is not as accurate as the laboratory-based α-defensin immunoassay: a systematic review and meta-analysis.

α-defensin is a biomarker which has been described as having a high degree of accuracy in the diagnosis of periprosthetic joint infection (PJI). Current meta-analyses are based on the α-defensin lab...

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide. The sensiti...

Phase II Cancer Clinical Trials for Biomarker-Guided Treatments.

The design and analysis of cancer clinical trials with biomarker depend on various factors, such as the phase of trials, the type of biomaker, whether the used biomarker is validated or not, and the s...

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic...

Medical and Biotech [MESH] Definitions

Techniques which study entities using their topological, geometric, or geographic properties and include the dimension of time in the analysis.

A type of analysis in which subjects in a study group and a comparison group are made comparable with respect to extraneous factors by individually pairing study subjects with the comparison group subjects (e.g., age-matched controls).

Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs.

A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.

Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.

More From BioPortfolio on "ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Trial